<DOC>
	<DOCNO>NCT00709982</DOCNO>
	<brief_summary>The purpose study assess effect folic acid administration blood level breakdown product OC study drug ( 250 mcg norgestimate [ NGM ] /35 mcg Ethinyl Estradiol [ EE ] ) tablet . The effect study drug tablet intake blood level folic acid also determine .</brief_summary>
	<brief_title>A Drug Interaction Study Folic Acid Oral Contraceptive Tablets Containing Norgestimate ( NGM ) /Ethinyl Estradiol ( EE ) Healthy Women .</brief_title>
	<detailed_description>This single-center , open-label , pharmacokinetic drug interaction study folic acid ( 1 mg ) study drug ( 250 mcg NGM/35 mcg EE ) 2 group least 20 healthy woman . In Group 1 , single oral dose 250 mcg NGM/35 mcg EE study drug administer healthy volunteer study site Days 1 17 folic acid 1 mg administer orally Days 4 18 ; Group 2 , folic acid 1 mg administer orally Days 1 17 study site 1 tablet study drug administer Days 2 17 . Blood sample collect specified time 72 hour postdose Days 1 17 healthy volunteer Group 1 determination blood level norelgestromin ( NGMN ) , norgestrel ( NG ) [ active breakdown product NGM ] , EE . For healthy volunteer Group 2 , blood sample collect 24 hour folic acid dose Days 1 17 determination plasma level total folate . Safety evaluate base following : incidence , type severity adverse event ; clinical laboratory test ; vital sign electrocardiogram ( ECGs ) measurement ; physical examination . Oral temperature , pulse , respiratory rate , sit blood pressure ( BP ) take dose Days 1 17 . For Group 1 , measurement take least 15 minute 24-hour ( Days 2 18 ) , 48-hour ( Days 3 19 ) , 72-hour ( Day 4 ) pharmacokinetic blood draw ; study completion ( Day 20 ) early withdrawal . For Group 2 , measurement take least 15 minute 24-hour pharmacokinetic blood draw Days 2 18 ; study completion ( Day 18 ) early withdrawal . Physical gynecologic examination 12-lead ECGs perform screen study completion early withdrawal . Blood sample blood chemistry , hematology , urine sample urinalysis collect screen visit follow-up visit early withdrawal . Oral contraceptive tablet ( 250 mcg NGM/35 mcg EE ) ; Folic acid tablet ( 1 mg ) . In Group 1 , single oral dose ( 250 mcg NGM/35 mcg EE ) study drug administer Days 1 17 folic acid 1 mg administer orally Days 4 18 ; Group 2 , folic acid 1 mg administer orally Days 1 17 1 tablet study drug administer Days 2 17 . Study drug take 240 mL ( 8 oz ) water approximately 8:00 a.m .</detailed_description>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Norgestimate</mesh_term>
	<mesh_term>Norgestrel</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Healthy , nonpregnant , nonlactating , nonsmoking woman , weigh least 110 pound With regular menstrual cycle A body mass index 16 29.9 kg/m2 And hematocrit least 36 % History presence disorder commonly accept contraindication sex hormonal therapy include : thromboembolic disorder ' cerebral vascular coronary artery disease , chronic untreated hypertension , migraine , benign malignant liver tumor develop use OC Known suspect estrogendependent neoplasia Presence disorder commonly accept contraindication combine OC include : undiagnosed abnormal vaginal bleeding , neurovascular lesion eye serious visual disturbance , liver disease Intake multivitamin folic acidcontaining supplement within 21 day study admission Used steroid hormonecontaining intrauterine device within 3 month study admission Used medication know cytochrome P450 enzyme inducer inhibitor ( e.g. , St. John 's Wort , cimetidine rifampin ) , within 60 day dose</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Norgestimate</keyword>
	<keyword>Contraceptives , Oral</keyword>
	<keyword>Ortho-Cyclen</keyword>
	<keyword>Folic Acid</keyword>
	<keyword>Ethinyl Estradiol</keyword>
</DOC>